A cautious culture cost Novo Nordisk its lead in the obesity drug race, former employees say

Taking stock of the drug industry, from the lab to the medicine chest

June 5, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Molly Ferguson for STAT STAT+ | A cautious culture cost Novo Nordisk its lead in the obesity drug race, former employees say Novo Nordisk's stock is down, the CEO is out, and Eli Lilly is ascendant. Danish drugmaker projects confidence, but R&D veterans say caution carried a cost. By Elaine Chen STAT+ | MoonLake Immunotherapeutics is for sale? This sounds like a cry for help In this week's edition of Adam's Biotech Scorecard, Adam also takes on the PD(L)1-VEGF antibody cancer treatments garnering so much attention. By Adam Feuerstein Rewriting of Covid vaccine recommendations has doctors and other experts worried New policy expected to result in Covid shots being harder to access, with fewer doctors choosing to stock them, fewer pharmacies willing to administer them. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser